Inamed, Genzyme Win OK for Wrinkle Gel

Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth.

Inamed, which already sells other wrinkle fillers, will compete with Medicis Pharmaceutical Corp.’s Restylane, which won U.S. approval in December.

Shares of Santa Barbara-based Inamed rose $2 to $55.50 on Nasdaq. Genzyme shares fell 64 cents to $46.46, also on Nasdaq.